Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-01 - Cannabis
Description
The participating funds aim to conclude discount contracts with all suitable pharmaceutical companies for cannabis (for the division into lots, see below) in accordance with § 130a para. 8 in conjunction with § 31 para. 6 SGB V. The contract is concluded within the framework of the Open-House-Originale procedure of the participating funds: Individual negotiations on contract contents are not conducted, uniform conditions apply. The participating health insurers do not guarantee exclusivity to individual contracting partners. The contract period is a maximum of 24 months, beginning on 01.04.2026. The contract ends at the latest on 31.03.2028, regardless of the date of contract conclusion. Joining this Open-House-Originale procedure is possible at any time during the contract period. All further information can be found in the participation and contract documents.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Medical equipments – Beschaffung eines OPMEG-Systems inklusive magnetischer Abschirmung
Universitätsklinikum Bonn AöRGermanyMedical equipmentsDeadline in 28 daysPublished on Sep 06, 2026
Germany – Personal care products – Rahmenvertrag über Lieferung von Toilettenpapier / Papierfalthandtücher / flüssige Handwaschseife (GB StMUV)
Freistaat Bayern, vertreten durch das Bayerische Landesamt für UmweltGermanyPersonal care productsSoapToilet paperDeadline in 29 daysPublished on Sep 06, 2026
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
KKH Kaufmännische KrankenkasseGermanyPharmaceutical productsDeadline in 115 daysPublished on Sep 06, 2026
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
KKH Kaufmännische KrankenkasseGermanyPharmaceutical productsDeadline in 115 daysPublished on Sep 06, 2026